CLINICAL TRIAL of P-1742 TOPICAL OR FLUPEROLONE (9 IPLUORO-21 METHYL PREDNISOLONE) in PSORIASIS by Khoo Oon Teik, Fung Wye Poh (Skin Clinic, Dept

Total Page:16

File Type:pdf, Size:1020Kb

CLINICAL TRIAL of P-1742 TOPICAL OR FLUPEROLONE (9 IPLUORO-21 METHYL PREDNISOLONE) in PSORIASIS by Khoo Oon Teik, Fung Wye Poh (Skin Clinic, Dept Vp1.5, No. 2. - SINGAPORE MEDICAL JOURNAL 6g June, 1964. CLINICAL TRIAL OF P-1742 TOPICAL OR FLUPEROLONE (9 IPLUORO-21 METHYL PREDNISOLONE) IN PSORIASIS By Khoo Oon Teik, Fung Wye Poh (Skin Clinic, Dept. of Clinical Medicine, University of Singapore). and Koh Kim Yam (Middle Road Hospital, Singapore). The use of triamcinolone in Psoriasis is now OBJECTS OF THE TRIAL WERE well established (Cohen and Baer 1960; Readett 1. to determine the effectiveness of P-1742 1961). However topical triamcinolone therapy topical as against has only lately come into prominence and the triamcinolone Aceto- nide cream. employment of triamcinolone cream with occlusion of the area from air by a non -porous 2. to compare the regime as against pre- covering was shown to be of even greater vious therapy. benefit by Frank and Rapp, 1963. 3. to evaluate the effectiveness of an occlusive agent. Recently, Chas Pfizer & Co. has announced preliminary trials with a new corticosteroid RESULTS: preparation, P-1742 or fluperolone (9 -fluoro -21 Table lists the cases treated methyl Prednisolone) in the treatment of der- l:- The cases were graded thus: - matoses. The results suggested superiority over ISQ = no change in the lesions triamcinolone cream. In view of the decided action of triamcinolone acetonide in Psoriasis, O = worse, when lesions became it was decided to evaluate the action of topical redder, more scaly and thicker. fluperolone in psoriasis, and to compare its' F + = marked improvement, when action with triamcinolone acetonide cream. lesions almost cleared up com- pletely. METHOD ++ = fair or moderate improvement The cases chosen for the trial were either as shown by less erythema, those cases previously treated with other agents scaling, and thickness. or new cases without previous therapy. One f = slight improvement. qualification was considered necessary i.e. the lesions whether discrete, discoid, guttate, or Table 11.: shows comparison between treat- generalised, must be bilateral and symmetrical ment with fluperolone, triamcinolone acetonide, and approximately of the same area involved. and the old treatment with topical tar ointment and ultra-violet irradiation. (The ointment Throughout the trial the right half of the contained liquor picis carbonis 6, salicylic acid body or the right limb or the right half of the 4, Ung H.A.D. to 100). face was treated with P-1742 topical, while the other half with a standard triamcinolone Side effects no side effects were noticed. Acetonide preparation (Kenacort A -Squibb). Discussion: In a chronic illness such as The cream was applied twice - a day for 10 days psoriasis any shortening of the period of treat- or 2 weeks, when the case was inspected and ment is a definite gain. In Singapore, where the progress by checked the same investigator the weather is always humid and hot the and photographed again. If little or no im- greater part of the year, it was generally felt provement was noted, the area treated was that any occlusive type of therapy would be occluded from air with polythene material very uncomfortable, and not tolerated by the the edges being fixed by Norbocutane Spray patients. However only 2 cases out of 11 cases (Evans) or Scotch tape, the part having been were unable to take this occlusive form of treated with the cream first. treatment and in these 2 cases the lesions RESULTS WITHOUT OCCLUSION RESULTS WITH OCCLUSION CASE TYPE OF RACE SEX AGE ODURATIONF DISEASE No. (in years) LESIONS on years) RIGHTSIDE(F) LEFT SIDE(T) RIGHT SIDE(F) LEFT SIDE(T) LINEAR 1 CH F 19 PLAQUE I +++ +++ ISQ I S Q 2 CH M 42 DISCRETE 7 + + 3 IND F 18 GUTTATE 2 + + + ++ CIRCINATE 4 CH M 19 AND DISCOID 2 ++ + DISCOID -1-1- 5 IND M 44 AND GUTTATE I + + + MULTIPLE G CH M 48 D 2 + + + +-1- MULTIPLE 7 CH F 26 6 0 0 0 0 DIFFUSE 0 8 CH F 42 PLAQUES 2 0 0 0 MULTIPLE B 9 CH M 43 DISCOID + + + + + 0 + 10 CH F 55 ANDADISCOID 15 0 PATCHY 11 IND M 27 AND OVOID 7 + + ++ ++1 12 IND M 23 PATCHY 12 + ++ + ++ 13 IND M 30 GUTTATE 4 ++ ++ ++ ++ TABLE . = = +++ - Marked Improvement I (F) FLUPEROLONE CH CHINESE ++ = Fair 1 (T)=TRIAMCINOLONE IND = IN DIRN = » + Slight ISQ= No change . ACETONIDE 0 =Worse. JUNE, 1964 71 CASE P-1742 TRIAMCINOLONE TAR . No. FLUPEROLONE ACETONIDE 1 +-i+ +++ ISQ 2 + ÷ I S Q 3 + ++ + 4 ++ + + 6 + ++ ISQ 7 0 0 ISQ 8 0 0 I S Q 9 + + 0 10 0 + I S Q 5 + ++ No previous 11 ++ ++ treatment 12 + ++ with TAR 13 -f-+ ++ TABLE IL. Comparison between Fluperolone and Triamcinolone and Tar. +++ = Marked Improvement. 0 = worse = Fair If ISQ = No change. + = Slight 'i 72 SINGAPORE MEDICAL JOURNAL became worse and they preferred the old side of the body or the left limbs, for a period treatment with tar. of 10 days to 2 weeks, after which occlusive treatment with a plastic cover was instituted From Table II, it would appear that flupero- for a further one to two weeks in 11 cases. lone and triamcinolone are superior to the treatment of topical tar ointment. There was It would appear that P-1742 (fluperolone) improvement in 10 out of the 13 cases with topical cream is somewhat less effective than fluperolone, and 11 out of the 13 cases with triamcinolone acetonide, but both were superior triamcinolone; and in one of these the condi- to the previous treatment with Tar. tion was markedly improved. However on Our impression is that in patients able to comparing fluperolone with triamcinolone, it tolerate occlusive therapy, there is a better would appear that triamcinolone was superior improvement in a significant number of to fluperolone in 5 cases, while fluperolone patients. was superior to triamcinolone in one case, and in 5 cases they were equally effective. ACKNOWLEDGEMENT Of the 11 cases under occlusive therapy, 2 We are grateful to Dr. Kirkup of Chas. became worse, but were no worse than without Pfizer & Co. for providing the fluperolone occlusion. Of the other 9 cases previously cream. The triamcinolone acetonide cream is treated with non -occlusive therapy, 4 showed marketed as Kenacort A (Squibb) cream. definite improvement, 4 were unchanged, and I failed to maintain previous improvement, on REFERENCES occlusion of the lesions. Cohen H. J. and Baer R. L. Invest. Derm. 34:271, 1960. SUMMARY AND CONCLUSION Readett M. D. Brit. J. Derm. 73: 107, 1961. Lawrence Frank and Y. Rapp. Arch. Derm. 87: 1, 13 cases of psoriasis of 1 year to 15 years 1963. duration were treated with fluperolone oint- New York Evaluation of Fluperolone Chas. Pfizer & ment on the right side of the body or the right Co. 1962. limbs, and triamcinolone acetonide on the left Oswald Morton. Brit. J. Derm. 74: 10, 1962. .
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • SUPPLEMENTARY APPENDIX 4: Search Strategies Syntax Guide For
    SUPPLEMENTARY APPENDIX 4: Search Strategies Pubmed, Embase Perioperative Management - PubMed Search Strategy – March 6, 2016 Syntax Guide for PubMed [MH] = Medical Subject Heading, also [TW] = Includes all words and numbers in known as MeSH the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [SH] = a Medical Subject Heading [TIAB] = Includes words in the title and subheading, e.g. drug therapy abstracts [MH:NOEXP] = a command to retrieve the results of the Medical Subject Heading specified, but not narrower Medical Subject Heading terms Boolean Operators OR = retrieves results that include at least AND = retrieves results that include all the one of the search terms search terms NOT = excludes the retrieval of terms from the search Perioperative Management PubMed Search Strategy – March 6, 2016 Search Query #1 ((((ARTHROPLASTY, REPLACEMENT, HIP[MH] OR HIP PROSTHES*[TW] OR HIP REPLACEMENT*[TIAB] OR HIP ARTHROPLAST*[TIAB] OR HIP TOTAL REPLACEMENT*[TIAB] OR FEMORAL HEAD PROSTHES*[TIAB]) OR (ARTHROPLASTY, REPLACEMENT, KNEE[MH] OR KNEE PROSTHES*[TW] OR KNEE REPLACEMENT*[TW] OR KNEE ARTHROPLAST*[TW] OR KNEE TOTAL REPLACEMENT*[TIAB]) OR (ARTHROPLAST*[TW] AND (HIP[TIAB] OR HIPS[TIAB] OR KNEE*[TIAB])) AND (("1980/01/01"[PDAT] : "2016/03/06"[PDAT]) AND ENGLISH[LANG])) NOT (((("ADOLESCENT"[MESH]) OR "CHILD"[MESH])
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,569,839 B1 Mckay (45) Date of Patent: May 27, 2003
    USOO6569839B1 (12) United States Patent (10) Patent No.: US 6,569,839 B1 McKay (45) Date of Patent: May 27, 2003 (54) FAST-ACTING PHARMACEUTICAL 5,875,776 A * 3/1999 Vaghefi ................. 128/203.15 COMPOSITIONS AND METHODS OF USE FOREIGN PATENT DOCUMENTS (76) Inventor: Douglas William McKay, 450 Moosa EP O 401 016 A1 5/1990 Blvd., Suite C, Eunice, LA (US) 70535 EP O 513 858 A2 11/1992 FR T405574 2/1974 (*) Notice: Subject to any disclaimer, the term of this GB 2 262 165 A 7/1991 patent is extended or adjusted under 35 WO WO 86-O1412 3/1986 U.S.C. 154(b) by 0 days. WO WO 87/00759 2/1987 WO WO 91/12830 9/1991 (21) Appl. No.: 09/449,637 * cited by examiner (22) Filed: Nov.30, 1999 Primary Examiner Raymond Henley, III Related U.S. Application Data ASSistant Examiner-Donna Jagoe (74) Attorney, Agent, or Firm-McDermott, Will & Emery (63) Continuation-in-part of application No. 09/154,520, filed on Sep. 16, 1998, now Pat. No. 6,325,788. (57) ABSTRACT (51) Int. Cl." ...................... A61K 31/727; A61K 31/56: A pharmaceutical composition comprising at least one local A61K 31/43; A61K 31/40 anesthetic, at least one anti-inflammatory agent and at least (52) U.S. CI. 514/54; 514/56; 514/59; one antibiotic are disclosed. The local anesthetic has a peak 51 4/169,514/19s, 51 4/411; 51 4sis. 514issi effect no later than about 10 minutes after administration to (58) Field of search s s 51454 5659 a mammal, and the anesthetic and anti-inflammatory have a half-life of no greater than about 36 hours after administra 514/169, 198, 411, 818, 887 tion.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Page 1 FINLANDS FÖRFATTNINGSSAMLING Utgiven I Helsingfors
    FINLANDS FÖRFATTNINGSSAMLING MuuMnrovvvvBeslutom läkemedelsförteckning asia av Säkerhets- och utvecklingscentret för läkemedelsområdet Utgiven i Helsingfors den 23 mars 2016 201/2016 Beslut av Säkerhets- och utvecklingscentret för läkemedelsområdet om läkemedelsförteckning Säkerhets- och utvecklingscentret för läkemedelsområdet har med stöd av 83 § i läke- medelslagen av den 10 april 1987 (395/1987) beslutat fastställa följande läkemedelsför- teckning: 1§ Förteckningens syfte Föreliggande beslut innehåller en förteckning över ämnen och droger som används medicinskt i Finland. Läkemedelsförteckningen upprättas med beaktande av bestämmel- serna i 3 och 5 § i läkemedelslagen. Med läkemedel avses ett preparat eller ämne vars ändamål är att vid invärtes eller ut- värtes bruk bota, lindra eller förebygga sjukdomar eller sjukdomssymtom hos människor eller djur. Som läkemedel betraktas också ett sådant ämne eller en sådan kombination av ämnen för invärtes eller utvärtes bruk som kan användas för att genom farmakologisk, im- munologisk eller metabolisk verkan återställa, korrigera eller modifiera fysiologiska funk- tioner eller utröna hälsotillståndet eller sjukdomsorsaker hos människor eller djur. Läkemedelsförteckningen är inte uttömmande. Till läkemedel räknas även sådana äm- nen och droger som inte nämns i denna förteckning men som uppfyller definitionen av lä- kemedel i läkemedelslagen. Utöver fastställande av läkemedelsförteckningen beslutar Säkerhets- och utvecklings- centret för läkemedelsområdet med stöd av 6 § i läkemedelslagen vid behov om ett ämne eller ett preparat ska betraktas som ett läkemedel. Centret beslutar separat i respektive fall om ett preparat som innehåller ett ämne i förteckningen ska betraktas som ett läkemedel med beaktande av produktens framställningssätt, sammansättning, dess farmakologiska egenskaper, hur det används, dess spridning, hur känt det är hos konsumenterna och de ris- ker som kan vara förenade med dess användning.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • United States Patent (10) Patent No.: US 9.447,027 B2 Milan Et Al
    US009447027B2 (12) United States Patent (10) Patent No.: US 9.447,027 B2 Milan et al. (45) Date of Patent: Sep. 20, 2016 (54) TREATING LONG QT SYNDROME 2004/O1972.71 A1* 10, 2004 Kunka et al. ................... 424/45 2006/0173058 A1* 8, 2006 Brown .................... CO7C 65/05 514,381 (75) Inventors: Es l, St. MS 2006/0173508 A1* 8, 2006 Stone ................. A61N 1,36085 aVId S. Peal, SomerV11 le. (US) 607/40 (73) Assignee: The General Hospital Corporation, FOREIGN PATENT DOCUMENTS Boston, MA (US) JP 11209328 A1 * 8, 1999 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 86 days. Nademanee, K. et al., Annals of the New York Academy of Sciences vol. 522, pp. 536-552, published 2006.* (21) Appl. No.: 13/822,264 Chouabe, C. et al., Molecular Pharmacology vol. 54 pp. 696-703, published 1998.* (22) PCT Filed: Oct. 20, 2011 Nishizawa, S., et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.e1-1167.e3, published Nov. 2009).* (86). PCT No.: PCT/US2011/057087 Nishizawa et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.el -1167.e3, published Nov. 2009).* S 371 (c)(1), Nishizawa et al (American Journal of Emergency Medicine vol. 27. (2), (4) Date: Jul. 22, 2013 pp. 1167.e1-1167.e3, published Nov. 2009).* Anderson et al., “Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism.” Circula (87) PCT Pub. No.: WO2012/054718 tion 113:365-373, 2006, 10 pages.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]